This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Exact Sciences (EXAS) Q4 Earnings and Revenues Rise Y/Y
by Zacks Equity Research
Exact Sciences' (EXAS) fourth-quarter 2019 results reflect strong segmental performances.
Virus or No Virus, Investing Case in US Stocks Looks Solid!
by Tirthankar Chakraborty
U.S. stocks are heavily exposed to the domestic economy where data continues to improve. And even if skeptics worry about the virus outbreak, developed markets are more stable than emerging markets during chaotic times.
Radware (RDWR) Q4 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Radware (RDWR) delivered earnings and revenue surprises of -4.17% and -0.22%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Luminex (LMNX) Earnings and Revenues Beat Estimates in Q4
by Zacks Equity Research
Luminex's (LMNX) fourth-quarter earnings benefit from higher revenues and solid performance across System Sales, Service and Other Revenues. However, gross margin contraction remains a woe.
DaVita (DVA) Earnings Beat Estimates in Q4, Revenues Miss
by Zacks Equity Research
DaVita (DVA) gains from dialysis services in the United States in Q4.
STERIS (STE) Surpasses Q3 Earnings Estimates, Ups FY20 View
by Zacks Equity Research
STERIS' (STE) third-quarter fiscal 2020 results reflect strong segmental performances.
Myriad Genetics (MYGN) Misses Q2 Earnings & Revenue Estimates
by Zacks Equity Research
Myriad Genetics (MYGN) reports decline in Hereditary Cancer, GeneSight, Vectra and Prenatal revenues in Q2.
Omnicell (OMCL) Lags Q4 Earnings Estimates, Beats on Revenues
by Zacks Equity Research
Omnicell (OMCL) fourth-quarter 2019 results reflect strong segmental performances.
Pacific Biosciences (PACB) Reports Break-Even Earnings in Q4
by Zacks Equity Research
Pacific Biosciences (PACB) expects softness in first-quarter consumable sales.
Surmodics (SRDX) Q1 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Surmodics' (SRDX) fiscal first-quarter earnings benefit from higher revenues, segmental growth and strong fiscal 2020 outlook.
Cardinal Health (CAH) Q2 Earnings & Revenues Top Estimates
by Zacks Equity Research
Cardinal Health (CAH) fiscal second-quarter results benefit revenue growth and strong segmental performance. However, contraction in gross margin remains a concern.
Becton, Dickinson (BDX) Q1 Earnings Beat, Revenues Rise Y/Y
by Zacks Equity Research
Becton, Dickinson (BDX) sees softness in BD Medical unit, slashes FY20 view.
ABIOMED (ABMD) Earnings Beat Estimates in Q3, Revenues Miss
by Zacks Equity Research
Flagship Impella drives ABIOMED's (ABMD) fiscal third-quarter results; FY20 revenue guidance slashed.
Cardiovascular Systems (CSII) Loss Wider Than Estimates in Q2
by Zacks Equity Research
We are upbeat about Cardiovascular Systems' (CSII) year-over-year uptick in global Coronary and peripheral device revenues during Q2.
Haemonetics (HAE) Q3 Earnings & Revenues Beat, Margins Expand
by Zacks Equity Research
Haemonetics (HAE) fiscal third-quarter 2020 results reflect strong performances in Plasma and Hospital segments.
Boston Scientific (BSX) Q4 Earnings Beat, Margins Decline
by Zacks Equity Research
Boston Scientific (BSX) is steadily investing in new technologies as well as the global markets, reflecting its uptick in sales across most geographies in Q4.
QIAGEN (QGEN) Q4 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
QIAGEN (QGEN) registered revenue growth across majority of its geographies and each of its operating segments in Q4
Cerner (CERN) Earnings and Revenues Beat Estimates in Q4
by Zacks Equity Research
Cerner (CERN) fourth-quarter results benefit from higher revenues, gains in Licensed software, Technology resale, Professional and Managed services units, and international revenue growth.
Zimmer Biomet (ZBH) Q4 Earnings Top Estimates, Margins Grow
by Zacks Equity Research
Zimmer Biomet (ZBH) benefits from strong sales growth across all geographies as well as segmental strengths at CER.
Phibro (PAHC) Q2 Earnings Top Estimates, Revenues Fall Y/Y
by Zacks Equity Research
Phibro (PAHC) witnessed revenue decline in two of its core segments and contraction in operating margin in Q2.
McKesson (MCK) Q3 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
McKesson's (MCK) fiscal third-quarter results gain from higher revenues and solid show by U.S. Pharmaceutical and Specialty Solutions, Medical-Surgical Solutions and Other segments.
Accuray (ARAY) Moves to Strong Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Accuray (ARAY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Company News for Jan 30, 2020
by Zacks Equity Research
Companies In The News Are: ARAY, MTSI, CVLT, XLNX
Accuray (ARAY) Q2 Earnings Top Estimates, Gross Orders Fall
by Zacks Equity Research
Service revenues drive Accuray's (ARAY) Q2 results, gross margin expands.
Accuray (ARAY) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Accuray (ARAY) delivered earnings and revenue surprises of 114.29% and 0.38%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?